Influenza-like illness (ILI), also known as acute respiratory infection (ARI) and flu-like syndrome/symptoms, is a medical diagnosis of possible influenza or other illness causing a set of common symptoms.
Symptoms commonly include fever, shivering, chills, malaise, dry cough, loss of appetite, body aches and nausea, typically in connection with a sudden onset of illness. In most cases, the symptoms are caused by cytokines released by immune system activation. and are thus relatively non-specific.
Common causes of ILI include the common cold and influenza, which tends to be less common but more severe than the common cold. Still less common causes include side effects of many drugs and manifestations of many other diseases.
The causes of influenza-like illness range from benign self-limited illnesses such as gastroenteritis, rhinoviral disease, and influenza, to severe, sometimes life-threatening, diseases such as meningitis, sepsis, and leukemia.
Technically, any clinical diagnosis of influenza is a diagnosis of ILI, not of influenza. This distinction usually is of no great concern because, regardless of cause, most cases of ILI are mild and self-limiting. Furthermore, except perhaps during the peak of a major outbreak of influenza, most cases of ILI are not due to influenza. ILI is very common: in the United States each adult can average 1–3 episodes per year and each child can average 3–6 episodes per year.
Influenza in humans is subject to clinical surveillance by a global network of more than 110 National Influenza Centers. These centers receive samples obtained from patients diagnosed with ILI, and test the samples for the presence of an influenza virus. Not all patients diagnosed with ILI are tested, and not all test results are reported. Samples are selected for testing based on severity of ILI, and as part of routine sampling, and at participating surveillance clinics and laboratories. The United States has a general surveillance program, a border surveillance program, and a hospital surveillance program, all devoted to finding new outbreaks of influenza.
In most years, in the majority of samples tested, the influenza virus is not present (see figure). In the United States during the 2008–9 influenza season through 18 April, out of 183,839 samples tested and reported to the CDC, only 25,925 (14.1%) were positive for influenza. The percent positive reached a maximum of about 25%. The percent positive increases with the incidence of infection, peaking with the peak incidence of influenza (see figure). During an epidemic, 60–70% of patients with a clear influenza-like illness actually have influenza.
Samples are respiratory samples, usually collected by a physician, nurse, or assistant, and sent to a hospital laboratory for preliminary testing. There are several methods of collecting a respiratory sample, depending on requirements of the laboratory that will test the sample. A sample may be obtained from around the nose simply by wiping with a dry cotton swab.
Infectious diseases causing ILI include malaria, acute HIV infection, herpes, hepatitis C, Lyme disease, rabies, myocarditis, Q fever, dengue fever, poliomyelitis, pneumonia, measles, and many others.
Pharmaceutical drugs that may cause ILI include many biologics such as interferons or monoclonal antibodies. Chemotherapeutic agents also commonly cause flu-like symptoms. Other drugs associated with a flu-like syndrome include bisphosphonates, caspofungin or levamisole. A flu-like syndrome can also be caused by an influenza vaccine or other vaccines, and by opioid withdrawal in addicts.
Influenza-like illness is a nonspecific respiratory illness characterized by fever, fatigue, cough, and other symptoms that stop within a few days. Most cases of ILI are caused not by influenza but by other viruses (e.g., rhinoviruses, coronaviruses and respiratory syncytial virus, adenoviruses, and parainfluenza viruses). Less common causes of ILI include bacteria such as Legionella, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Streptococcus pneumoniae. Influenza, RSV, and certain bacterial infections are particularly important causes of ILI because these infections can lead to serious complications requiring hospitalization. Physicians who examine persons with ILI can use a combination of epidemiologic and clinical data (information about recent other patients and the individual patient) and, if necessary, laboratory and radiographic tests to determine the cause of the ILI.
During the 2009 swine flu outbreak many thousands of cases of ILI were reported in the media as suspected swine flu. Most were false alarms. A differential diagnosis of probable swine flu requires not only symptoms but also a high likelihood of swine flu due to the person's recent history. During the 2009 swine flu outbreak in the United States, the CDC advised physicians to "consider swine influenza infection in the differential diagnosis of patients with acute febrile respiratory illness who have either been in contact with persons with confirmed swine flu, or who were in one of the five U.S. states that have reported swine flu cases or in Mexico during the 7 days preceding their illness onset." A diagnosis of confirmed swine flu required laboratory testing of a respiratory sample (a simple nose and throat swab).
In rare cases
If a person with ILI also has either a history of exposure or an occupational or environmental risk of exposure to Bacillus anthracis (anthrax), then a differential diagnosis requires distinguishing between ILI and anthrax. Other rare causes of ILI include leukemia and metal fume fever.
ILI occurs in some horses after intramuscular injection of vaccines. For these horses, light exercise speeds resolution of the ILI. Non-steroidal anti-inflammatory drugs (NSAIDs) may be given with the vaccine.
- "Case definitions". European Influenza Surveillance Scheme. 12 December 2005. Retrieved 15 July 2009.
- Centers for Disease Control and Prevention (9 November 2001). "Considerations for distinguishing influenza-like illness from inhalational anthrax". Morbidity and Mortality Weekly Report 50 (44): 984–6. PMID 11724153.
- "2008–2009 Influenza Season Week 15 ending April 18, 2009". FluView: A Weekly Influenza Surveillance Report Prepared by the Influenza Division (Centers for Disease Control and Prevention). 24 April 2009. Retrieved 26 April 2009.
- "Flu Activity & Surveillance". Centers for Disease Control and Prevention. 17 April 2009. Retrieved 26 April 2009.
- "Influenza – Frequently asked questions". European Influenza Surveillance Scheme. 21 November 2005. Retrieved 28 April 2009.[dead link]
- Moore C, Corden S, Sinha J, Jones R (November 2008). "Dry cotton or flocked respiratory swabs as a simple collection technique for the molecular detection of respiratory viruses using real-time NASBA". Journal of Virological Methods 153 (2): 84–9. doi:10.1016/j.jviromet.2008.08.001. PMID 18761378.
- Chimenti C, Pieroni M, Frustaci A (April 2006). "Myocarditis: when to suspect and how to diagnose it in athletes". J Cardiovasc Med (Hagerstown) 7 (4): 301–6. doi:10.2459/01.JCM.0000219325.50622.93. PMID 16645406.
- Cologna R, Armstrong PM, Rico-Hesse R (January 2005). "Selection for virulent dengue viruses occurs in humans and mosquitoes". J Virol 79 (2): 853–9. doi:10.1128/JVI.79.2.853-859.2005. PMC 538581. PMID 15613313.
- Moses H, Brandes DW (September 2008). "Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis". Curr Med Res Opin 24 (9): 2679–90. doi:10.1185/03007990802329959. PMID 18694542.
- Antoniou C, Stefanaki I, Stratigos A, et al. (April 2007). "The Greek experience with efalizumab in psoriasis from a university dermatologic hospital". Br J Dermatol. 156 Suppl 2: 12–6. doi:10.1111/j.1365-2133.2007.07764.x. PMID 17371318.
- Reinisch W, Hommes DW, Van Assche G, et al. (August 2006). "A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease". Gut 55 (8): 1138–44. doi:10.1136/gut.2005.079434. PMC 1856289. PMID 16492717.
- Body JJ (August 2001). "Dosing regimens and main adverse events of bisphosphonates". Semin Oncol 28 (4 Suppl 11): 49–53. doi:10.1016/S0093-7754(01)90232-5. PMID 11544576.
- Scheinfeld N, Rosenberg JD, Weinberg JM (2004). "Levamisole in dermatology : a review". Am J Clin Dermatol 5 (2): 97–104. doi:10.2165/00128071-200405020-00004. PMID 15109274.
- Centers for Disease Control and Prevention (26 April 2009). "CDC Health Update: Swine Influenza A (H1N1) Update: New Interim Recommendations and Guidance for Health Directors about Strategic National Stockpile Materiel". Health Alert Network. Retrieved 27 April 2009.
- Centers for Disease Control and Prevention (CDC) (2 November 2001). "Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax". Morbidity and Mortality Weekly Report (Centers for Disease Control and Prevention) 50 (43): 941–8. PMID 11708591.
- Temte JL, Zinkel AR (September 2004–Oct). "The primary care differential diagnosis of inhalational anthrax.". Annals of Family Medicine 2 (5): 438–44. doi:10.1370/afm.125. PMC 1466714. PMID 15506578. Check date values in:
- Waterer GW, Robertson H (January 2009). "Bioterrorism for the respiratory physician.". Respirology 14 (1): 5–11. doi:10.1111/j.1440-1843.2008.01446.x. PMID 19144044.
- Loving, Nancy S (2006). All horse systems go : the horse owner's full-color veterinary care and conditioning resource for modern performance, sport, and pleasure horses. Trafalgar Square Publishing. OCLC 61864306. page 439